Selahattin Akcay

Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: their relationship to severity of coronary artery ectasia.

ObjectiveAlthough underlying mechanisms of coronary artery ectasia (CAE) are clearly unknown, destruction of extracellular matrix may be responsible for the ectasia formation. Thus, we investigated the role of matrix metalloproteinases (MMP), tissue inhibitor of matrix metalloproteinases (TIMP-1), and inflammatory markers [high-sensitive C-reactive protein, interleukins (ILs)] in CAE patients. MethodsThis study consisted of 28 consecutive CAE patients, 27 obstructive coronary artery disease (CAD) patients, and 22 controls with normal coronary arteries undergoing cardiac catheterization. Plasma levels of MMP-3, MMP-9, TIMP-1, and inflammatory markers were measured. ResultsPlasma level of MMP-3 was significantly higher in CAE patients compared with both CAD patients and controls (17.2±6.1, 11.2±3.2, and 9.2±3.4 ng/ml, respectively, both P=0.001) and so did MMP-9 level (27.4±5.9, 24.8±4.4, and 20.6±4.6 ng/ml, respectively, both P<0.05). IL-6 level was also higher in CAE patients than in controls (60.9±22.1 vs. 36.1±21.5 pg/ml, P=0.001) but were comparable in CAE and CAD patients. Plasma high-sensitive C-reactive protein, IL-1, and TIMP-1 levels were similar in three groups. MMP-3 levels correlated with diffuse (r=0.46, P=0.01) and multivessel ectasia (r=0.45, P=0.02). ConclusionOur results suggest that the increased level of MMP-3, MMP-9, and IL-6 may be responsible for ectasia formation in patients with CAE.

Mean platelet volume in patients with prehypertension and hypertension

Patients with hypertension have evidence of platelet activation. Mean platelet volume (MPV), an indicator of platelet activation has been shown to be elevated in patients with hypertension. Prehypertension is also associated with an increase in cardiovascular morbidity and mortality. The aim of this study was to assess the MPV in patients with prehypertension and hypertension. This study included newly diagnosed and untreated 87 prehypertensive patients, 30 hypertensive patients and 35 normotensive control subjects matched for age, gender, and body mass index. All patients and controls gave informed consent. The MPV values of patients with prehypertension and hypertension were significantly higher than those of the control group (8.4 +/- 0.8 and 8.8 +/- 0.7 versus 7.9 +/- 0.5 fl; p < 0.05 and p < 0.001 respectively). It was also higher in hypertensives than in prehypertensives (8.8 +/- 0.7 versus 8.4 +/- 0.8 fl; p < 0.05). However, we found that the presence of the hypertension (beta = 0.28, P = 0.003) was only significant predictors of higher MPV in a multivariable model that adjusted for other variables. We have shown that, MPV, an indicator of platelet activation was significantly higher in patients with prehypertension and hypertension when compared with control subjects. We have also showed that MPV was also higher in patients with hypertension than in patients with prehypertension. However, presence of the hypertension was only significant predictor of higher MPV.

Influence of obstructive sleep apnea on left ventricular mass and global function: sleep apnea and myocardial performance index.

Obstructive sleep apnea (OSA) is associated with cardiovascular mortality and morbidity. It may predispose patients to left ventricular hypertrophy and heart failure. The aim of this study was to determine the left ventricular mass (LVM) and myocardial performance index (MPI) reflecting left ventricular global function in uncomplicated OSA patients. Sixty-four subjects without hypertension, diabetes mellitus, and any cardiac or pulmonary disease referred for evaluation of OSA underwent overnight polysomnography and complete echocardiographic assessment. According to the apnea hypopnea index (AHI), subjects were divided into three groups: group 1, control subjects with nonapneic snorers (AHI < 5, n = 18); group 2, patients with mild to moderate OSA (AHI: 5–30, n = 25); and group 3, severe OSA (AHI > 30, n = 21). Basic echocardiographic measurements, LVM, and LVM index were measured. Left ventricular MPI was calculated as (isovolumic contraction time+isovolumic relaxation time)/aortic ejection time by Doppler echocardiography. There were no significant differences in age, sex, body mass index, heart rate, and systolic and diastolic blood pressure among the three groups. Left atrium, interventricular septum, left ventricular posterior wall, left ventricular end-diastolic and end-systolic diameters, LVM mass, and LVM index were not significantly different among the three groups. Left ventricular MPI was significantly higher in severe OSA patients (0.64 ± 0.18) than in controls (0.49 ± 0.18; P < 0.05). There was no significant difference between controls (0.49 ± 0.18) and mild to moderate OSA (0.61 ± 0.16; P = 0.08) and between mild to moderate OSA (0.61 ± 0.16) and severe OSA (0.64 ± 0.18; P = 0.84). The present study demonstrates that patients with severe OSA have global left ventricular dysfunction.

Impact of chronic fluorosis on left ventricular diastolic and global functions.

Sixty three patients with endemic fluorosis (36 males/27 females; mean age 33.9+/-8.6years) and 45 age, sex and body mass index (BMI) matched healthy controls (30 males/15 females; mean age 32.7+/-8.8years) were included in this study. Basic echocardiographic measurements, left ventricular diastolic parameters and left ventricular myocardial performance index (MPI) were measured. The left ventricular MPI was calculated as (isovolumic contraction time+isovolumic relaxation time)/aortic ejection time by Doppler. The urine fluoride levels of fluorosis patients were significantly higher than control subjects as expected (1.9+/-0.1mg/l vs 0.4+/-0.1mg/l respectively; P<0.001). Isovolumic relaxation time (IVRT) and deceleration time (DT) were significantly higher in fluorosis patients than in controls (for IVRT 106.9+/-15.6ms vs 96.7+/-12.2ms; P<0.001 and for DT 211.7+/-30.7ms vs 188.0+/-30.0ms; P<0.001, respectively). MPI was significantly higher in fluorosis patients than in controls (0.62+/-0.15ms vs 0.49+/-0.10ms; P<0.001, respectively). We have shown that chronic fluorosis patients had left ventricular diastolic and global dysfunctions.

Mean platelet volume is associated with insulin resistance in non-obese, non-diabetic patients with coronary artery disease

BACKGROUND AND PURPOSE Mean platelet volume (MPV), an indicator of platelet activation, has been shown to be elevated in patients with coronary artery disease (CAD) in some studies. Insulin resistance contributes to increased platelet activation and it is one of the risk factors for CAD. The aim of this study was to assess the relationship between insulin resistance and MPV in non-obese, non-diabetic patients with CAD. METHODS AND SUBJECTS Seventy-seven non-obese, non-diabetic CAD patients were divided into two groups, insulin resistant and insulin sensitive according to the homeostasis model assessment insulin resistance index (HOMA-IR). The insulin-resistant group was composed of 45 patients (30 males/15 females; mean age 59.8±11.1 years). The insulin-sensitive group was composed of 32 patients (17 males/15 females; mean age 58.9±12.2 years). RESULTS Insulin and HOMA-IR values were significantly higher in insulin-resistant CAD patients than in insulin-sensitive CAD patients. The MPV values were significantly higher in insulin-resistant CAD patients than in insulin-sensitive CAD patients (8.6±1.0 fl vs. 8.0±0.7 fl; respectively, p=0.01). The MPV was poorly correlated with HOMA-IR (r=0.30, p=0.054) and insulin (r=0.22, p=0.053). CONCLUSIONS We have shown that MPV was significantly elevated in insulin-resistant non-obese, non-diabetic CAD patients when compared to insulin-sensitive non-obese, non-diabetic CAD patients.

Mean platelet volume in patients with coronary artery ectasia.

Coronary artery ectasia (CAE) is a variant of coronary atherosclerosis. Mean platelet volume (MPV), an indicator of platelet activation, has been shown to be elevated in patients with acute coronary syndromes and myocardial infarction in the setting of obstructive coronary artery disease. The aim of this study was to assess the MPV in patients with CAE. We retrospectively studied 366 consecutive patients with CAE (195 men/171 women; mean age 55.4 ± 10.9 years) and 160 control patients (81 men/79 women; mean age 53.5 ± 10.2 years). MPV values were recorded in all study and control patients. The MPV values of patients with CAE were found to be significantly higher than those of the controls (9.2 ± 1.1 versus 8.8 ± 1.2 fl, respectively; P < 0.001). The platelet count was detected to be significantly lower in patients with CAE group than in patients with control group (233.7 ± 70.7 versus 264.7 ± 102.8 (×109/l), respectively; P < 0.0001). We have shown that MPV was significantly elevated in patients with CAE compared with controls.

The effect of pretreatment with renin-angiotensin-aldosterone system blockers on cardioversion success and acute recurrence of atrial fibrillation

Background:  Renin‐angiotensin‐aldosterone system (RAS) may be activated during atrial fibrillation (AF). It is unclear whether RAS inhibition may facilitate cardioversion from AF and may prevent acute recurrence of AF (ARAF). We thus investigated the effect of pretreatment with RAS blockers on cardioversion success and ARAF in patients with AF scheduled for elective cardioversion.